Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Imatinib 400 MG Oral Tablet
Sponsor: Vastra Gotaland Region
Collaborators: Sahlgrenska University Hospital, Sweden|Lund University